USMLE

Dabrafenib, Vemurafenib

3,812 views
Oncology Pharm
  1. Bleomycin
  2. Dactinomycin, Actinomycin D
  3. Doxorubicin, Daunorubicin
  4. Azathioprine, 6-MP
  5. Cladribine
  6. Cytarabine
  7. Busulfan
  8. Cyclophosphamide, Ifosfamide
  9. Nitrosoureas
  10. Paclitaxel
  11. Vincristine, Vinblastine
  12. Cisplatin, Carboplatin, Oxaliplatin
  13. Etoposide, Teniposide
  14. Irinotecan, Topotecan
  15. Bevacizumab
  16. Erlotinib
  17. Cetuximab, Panitumumab
  18. Imatinib, Dasatinib
  19. Rituximab
  20. Bortezomib, Carfilzomib
  21. Trastuzumab
  22. Dabrafenib, Vemurafenib
  23. Raloxifene and Tamoxifen
  24. Hydroxyurea
  25. Procarbazine

Summary

Vemurafenib and dabrafenib are both BRAF kinase inhibitors useful in the treatment of metastatic melanoma. Metastatic melanoma is often driven by activating mutations in the BRAF kinase gene, such as the V600E mutation that both drugs target.

Key Points

  • Vemurafenib / Dabrafenib
    • Mechanism
      • BRAF kinase inhibitor
        • Small molecule inhibitors of BRAF+ melanoma
        • VEmuRAF-enib is for V600E-mutated BRAF inhibition
    • Clinical use
      • Metastatic melanoma
        • Metastatic melanoma is often driven by an activation mutation in BRAF